Guardant Health Inc (GH)
Guardant Health, Inc. - Guardant Health Receives FDA Approval forGuardant360® CDx as Companion Diagnostic forBRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Guardant Health, Inc. - Guardant Health Receives FDA Approval forGuardant360® CDx as Companion Diagnostic forBRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical